Clinical Trial Update: A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD [Phase 2]

View source ↗

Summary

Phase II study evaluating surufatinib in combination with camrelizumab and the mFOLFOX6 regimen as second-line treatment for advanced pancreatic cancer; the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• MFOLFOX6
• Surufatinib (Surufatinib)

Snippet

Sponsor: Rui-hua Xu, MD, PhD | Conditions: Advanced Pancreatic Cancer | Phase 2 | Status: NOT_YET_RECRUITING